Compare Novartis AG (NVS) vs Toast Inc. Class A Common Stock (TOST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Toast Inc. Class A Common Stock — how do they compare? Novartis AG trades at $149.9 (market cap $271.82B), while Toast Inc. Class A Common Stock trades at $29.65 (market cap $17.85B). The key difference: Novartis AG is far larger — about 15.2× Toast Inc. Class A Common Stock's market cap, and Novartis AG pays a 3.33% dividend while Toast Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| NVS | TOST | |
|---|---|---|
Market Cap | $271.82B | $17.85B |
Volume | 1,841,354 | 6,311,718 |
Sector | Health | Technology |
52-Week High | $168.62 | $39.02 |
52-Week Low | $121.80 | $22.33 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $313.15B | $16.10B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $146.88, up 2.11% today, with a bearish technical signal from moving averages and an overbought RSI. The company reported revenue of $56.67B in 2025, with a net income margin of 22.5%, and recently announced a $7.8B licensing deal with China's Abogen for RNA-based therapy. Earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026.
The outlook is cautious due to recent clinical trial setbacks and investor scrutiny of M&A strategy. Analyst consensus is a $146 price target with a hold-heavy rating. Risks include pipeline failures and competitive pressures, but strong cash flow and profitability provide support.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Toast Inc. Class A Common Stock
Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →
